TradingKey

關於 Alnylam Pharmaceuticals Inc 公司

Alnylam Pharmaceuticals, Inc. 是一家商業階段的生物製藥公司。該公司致力於發現、開發、製造和商業化基於核糖核酸干擾 (RNAi) 的新型療法。其上市產品包括用於治療成人遺傳性轉甲狀腺素介導性澱粉樣變性 (hATTR) 伴多發性神經病的 AMVUTTRA (vutrisiran)；用於治療成人 hATTR 澱粉樣變性伴多發性神經病的 ONPATTRO (patisiran)；用於治療成人急性肝卟啉症的 GIVLAARI (givosiran)；用於治療 1 型原發性高草酸尿症的 OXLUMO (lumasiran)，以及由其合作伙伴諾華公司開發和商業化的 Leqvio (inclisiran)，用於治療成人高膽固醇血癥或混合性血脂異常。該公司的臨牀開發項目包括 Cemdisiran、Fitusiran、Zilebesiran、Elebsiran、Mivelsiran 和 ALN-HTT02。該公司正在開發 Cemdisiran 來治療補體介導的疾病。

公司簡介

公司代碼ALNY

公司名稱Alnylam Pharmaceuticals Inc

上市日期May 28, 2004

成立日期2003

CEODr. Yvonne L. Greenstreet, M.D.

員工數量2230

證券類型Ordinary Share

年結日May 28

公司地址675 W Kendall St

城市CAMBRIDGE

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編02142-1168

電話16175518200

網址https://www.alnylam.com/

公司代碼ALNY

上市日期May 28, 2004

成立日期2003

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

49.35K

--

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

47.81K

+40.80%

Mr. Tolga Tanguler

Chief Commercial Officer

28.01K

+95.27%

Mr. Michael W. (Mike) Bonney

Chief Compliance Officer, Director

20.80K

+3.87%

Dr. Dennis A. Ausiello, M.D.

Independent Director

4.41K

+21.31%

Dr. Margaret A. Hamburg, M.D.

Independent Director

911.00

+569.85%

Ms. Carolyn R. Bertozzi, M.D.

Independent Director

775.00

--

Dr. Olivier Brandicourt, M.D.

Independent Director

775.00

--

Mr. Peter N. Kellogg

Independent Director

775.00

--

Ms. Colleen F. Reitan

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

49.35K

--

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

47.81K

+40.80%

Mr. Tolga Tanguler

Chief Commercial Officer

28.01K

+95.27%

Mr. Michael W. (Mike) Bonney

Chief Compliance Officer, Director

20.80K

+3.87%

Dr. Dennis A. Ausiello, M.D.

Independent Director

4.41K

+21.31%

Dr. Margaret A. Hamburg, M.D.

Independent Director

911.00

+569.85%

收入明細

單位: USD更新時間: 7月6日週日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

業務USD

名稱

營收

佔比

AMVUTTRA

309.99M

52.17%

GIVLAARI

66.97M

11.27%

Other

57.56M

9.69%

Regeneron Pharmaceuticals

51.04M

8.59%

ONPATTRO

49.49M

8.33%

Other

59.15M

9.95%

地區USD

名稱

營收

佔比

United States

271.44M

45.68%

Europe

146.16M

24.60%

Net revenues from collaborations

99.19M

16.69%

Rest of World

50.94M

8.57%

Royalty revenue

26.47M

4.45%

業務

地區

業務USD

名稱

營收

佔比

AMVUTTRA

309.99M

52.17%

GIVLAARI

66.97M

11.27%

Other

57.56M

9.69%

Regeneron Pharmaceuticals

51.04M

8.59%

ONPATTRO

49.49M

8.33%

Other

59.15M

9.95%

股東統計

更新時間: 5月17日週六

持股股東

股東類型

持股股東

佔比

Capital World Investors

12.85%

Fidelity Management & Research Company LLC

11.22%

The Vanguard Group, Inc.

9.97%

Capital Research Global Investors

5.49%

BlackRock Institutional Trust Company, N.A.

5.16%

Other

55.32%

持股股東

佔比

Capital World Investors

12.85%

Fidelity Management & Research Company LLC

11.22%

The Vanguard Group, Inc.

9.97%

Capital Research Global Investors

5.49%

BlackRock Institutional Trust Company, N.A.

5.16%

Other

55.32%

股東類型

持股股東

佔比

Investment Advisor

67.07%

Investment Advisor/Hedge Fund

20.96%

Corporation

3.41%

Hedge Fund

3.13%

Sovereign Wealth Fund

1.98%

Research Firm

1.57%

Pension Fund

1.29%

Bank and Trust

1.12%

Individual Investor

0.40%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

1290

132.21M

101.40%

-2.93M

2025Q1

1315

132.55M

101.67%

-2.42M

2024Q4

1263

130.73M

100.99%

-1.47M

2024Q3

1225

126.90M

98.51%

-1.26M

2024Q2

1183

123.30M

96.32%

+1.12M

2024Q1

1172

117.88M

93.23%

-5.46M

2023Q4

1169

120.70M

96.18%

-5.54M

2023Q3

1125

121.55M

96.89%

-6.15M

2023Q2

1119

122.11M

98.30%

-6.32M

2023Q1

1116

123.13M

99.37%

-5.56M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

Capital World Investors

16.75M

12.85%

+149.10K

+0.90%

Mar 31, 2025

Fidelity Management & Research Company LLC

14.62M

11.22%

+1.68M

+13.00%

Mar 31, 2025

The Vanguard Group, Inc.

13.00M

9.97%

+322.72K

+2.55%

Mar 31, 2025

Capital Research Global Investors

7.15M

5.49%

+186.22K

+2.67%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

6.73M

5.16%

-22.21K

-0.33%

Mar 31, 2025

Regeneron Pharmaceuticals Inc

4.44M

3.41%

--

Mar 31, 2025

T. Rowe Price Investment Management, Inc.

4.42M

3.39%

+33.70K

+0.77%

Mar 31, 2025

Baillie Gifford & Co.

3.66M

2.81%

-382.65K

-9.47%

Mar 31, 2025

T. Rowe Price Associates, Inc.

3.41M

2.61%

+178.26K

+5.52%

Mar 31, 2025

State Street Global Advisors (US)

3.37M

2.58%

-56.29K

-1.64%

Mar 31, 2025

持股ETF

更新時間: 7月6日週日

機構名稱

佔比

Tema Neuroscience and Mental Health ETF

5.92%

VanEck Biotech ETF

5.43%

Global X Genomics & Biotechnology ETF

5.37%

Invesco Nasdaq Biotechnology ETF

4.43%

ProShares Ultra Nasdaq Biotechnology

4.22%

First Trust NYSE Arca Biotechnology Index Fund

4.02%

iShares Biotechnology ETF

3.98%

American Century Focused Dynamic Growth ETF

3.44%

Franklin Genomic Advancements ETF

3.41%

SPDR S&P Biotech ETF

2.75%

Tema Neuroscience and Mental Health ETF

佔比5.92%

VanEck Biotech ETF

佔比5.43%

Global X Genomics & Biotechnology ETF

佔比5.37%

Invesco Nasdaq Biotechnology ETF

佔比4.43%

ProShares Ultra Nasdaq Biotechnology

佔比4.22%

First Trust NYSE Arca Biotechnology Index Fund

佔比4.02%

iShares Biotechnology ETF

佔比3.98%

American Century Focused Dynamic Growth ETF

佔比3.44%

Franklin Genomic Advancements ETF

佔比3.41%

SPDR S&P Biotech ETF

佔比2.75%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Alnylam Pharmaceuticals Inc

401.800USD

Alnylam Pharmaceuticals Inc

401.800

概覽

公司

財務